These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11503777)

  • 21. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sunscreen drug products for over-the-counter human use; final monograph. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 May; 64(98):27666-93. PubMed ID: 10558542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.
    Fed Regist; 1999 Oct; 64(192):54180-9. PubMed ID: 11010702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(114):35290-3. PubMed ID: 12807133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(90):31123-5. PubMed ID: 12001971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical antifungal drug products for over-the-counter human use; amendment of final monograph. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Aug; 65(168):52302-5. PubMed ID: 11067736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 1999 May; 64(93):26282-7. PubMed ID: 10558530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Child-resistant packaging for certain over-the-counter drug products. Final rule.
    Consumer Product Safety Commission
    Fed Regist; 2001 Aug; 66(149):40111-6. PubMed ID: 11732555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Revision to requirements for licensed Anti-Human Globulin and Blood Grouping Reagents. Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 2000 Dec; 65(239):77497-9. PubMed ID: 11503726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical devices; establishment registration and device listing for manufacturers and distributors of devices; correction--FDA. Proposed rule; correction.
    Fed Regist; 1998 Nov; 63(228):65566. PubMed ID: 10338876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical devices; preemption of state product liability claims--FDA. Withdrawal of proposed rule.
    Fed Regist; 1998 Jul; 63(142):39789-90. PubMed ID: 10181516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Foreign Establishment Registration and United States agent requirements.
    Nolte CJ; McNamara-Cullinane M
    Med Device Technol; 2002 Dec; 13(10):32-3. PubMed ID: 12575528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Labeling of diphenhydramine-containing drug products for over-the-counter human use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(235):72555-9. PubMed ID: 12474879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Revisions to the general safety test requirements for biological products--FDA. Direct final rule: confirmation in part and withdrawal in part.
    Fed Regist; 1998 Aug; 63(150):41718. PubMed ID: 10181723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sterility requirement for aqueous-based drug products for oral inhalation. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 May; 65(103):34082-9. PubMed ID: 11010719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical devices; preemption of state product liability claims--FDA. Proposed rule.
    Fed Regist; 1997 Dec; 62(239):65384-8. PubMed ID: 10176832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality mammography standards. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
    Fed Regist; 1999 Jun; 64(116):32404-7. PubMed ID: 10558582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Jan; 65(4):1000-50. PubMed ID: 11010621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Registration of food facilities under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(190):57505-9. PubMed ID: 16200686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.